@prefix ns1: <https://w3id.org/biolink/vocab/> .
@prefix ns2: <https://w3id.org/neurodkg/> .
@prefix ns3: <https://schema.org/> .
@prefix ns4: <http://www.w3.org/ns/prov#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .

<http://purl.obolibrary.org/obo/DOID_5419> ns3:possibleTreatment <http://purl.org/np/RA2zKLyAuyeo6cHTfOknawUYaRg4M4pUeliAern9R_sJ8#medtherapy> .

<http://purl.org/np/RA7Fr6GJBnZ1EWjb4jKbsXbMnXDFqC5xesUxcdYEkX5LM#association> a rdf:Statement ;
    rdfs:label "Lorazepam injection is indicated for the treatment of status epilepticus." ;
    rdf:object <https://identifiers.org/HP:0032659> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:52993> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae274b1f-27c3-483b-99f1-9a9249dc2459> ;
    ns1:relation ns3:TreatmentIndication .

<http://purl.org/np/RA7k_pk6RqgntjF86QAJhA1fHTohtxaP1CjCCcF74Cdr0#association> a rdf:Statement ;
    rdfs:label "Almotriptan tablets (almotriptan malate) are indicated for the acute treatment of migraine attacks in patients with a history of migraine with or without aura" ;
    rdf:object <https://identifiers.org/MONDO:0043537> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:520985> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RA7k_pk6RqgntjF86QAJhA1fHTohtxaP1CjCCcF74Cdr0#cohort> ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35617039-9f33-401b-bac3-8f85c65fa2c7> ;
    ns1:relation ns3:TreatmentIndication .

<http://purl.org/np/RA7wRogkbsj2tbG4zG0Mb1DiD0xuzAo0MWsw8wFwkQ45Q#association> a rdf:Statement ;
    rdfs:label "PRIALT (ziconotide) solution, intrathecal infusion is indicated for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine" ;
    rdf:object <https://identifiers.org/MONDO:0021668> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:142406> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RA7wRogkbsj2tbG4zG0Mb1DiD0xuzAo0MWsw8wFwkQ45Q#cohort> ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1> ;
    ns1:relation <https://w3id.org/um/neurodkg/SymptomaticReliefIndication> .

<http://purl.org/np/RA8nK1kh1RiuFaqP-RHp2tpAeYCfxufGdy9GZpk3-8LLk#association> a rdf:Statement ;
    rdfs:label "Amantadine hydrochloride capsules are indicated in the treatment of idiopathic Parkinson’s disease (Paralysis Agitans), postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis.It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis." ;
    rdf:object <https://identifiers.org/MONDO:0006966> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:2619> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RA8nK1kh1RiuFaqP-RHp2tpAeYCfxufGdy9GZpk3-8LLk#cohort> ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=491aea85-5a55-4a7c-b1cf-a123fea4377d> ;
    ns1:relation ns3:TreatmentIndication .

<http://purl.org/np/RADb9I2Nhsc9xqG2L9Ok6yo7Fha2yvvtCDkiyFZP5476Q#association> a rdf:Statement ;
    rdfs:label "Lorazepam injection is indicated in adult patients for preanesthetic medication, producing sedation (sleepiness or drowsiness), relief of anxiety, and a decreased ability to recall events related to the day of surgery. It is most useful in those patients who are anxious about their surgical procedure and who would prefer to have diminished recall of the events of the day of surgery" ;
    rdf:object <https://identifiers.org/MONDO:0005618> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:52993> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae274b1f-27c3-483b-99f1-9a9249dc2459> ;
    ns1:relation <https://w3id.org/um/neurodkg/SymptomaticReliefIndication> .

<http://purl.org/np/RAG6t1GxGSN6RH1EqWONkBadVZPC5SOawHe6FAYjKujkc#association> a rdf:Statement ;
    rdfs:label "EMGALITY is indicated for the preventive treatment of migraine in adults." ;
    rdf:object <https://identifiers.org/MONDO:0005277> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/UNII:55KHL3P693> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RAG6t1GxGSN6RH1EqWONkBadVZPC5SOawHe6FAYjKujkc#cohort> ;
    ns1:provided_by <https://w3id.org/um/NeuroDKG> ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33a147be-233a-40e8-a55e-e40936e28db0> ;
    ns1:relation ns3:PreventionIndication .

<http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#association> a rdf:Statement ;
    rdfs:label "Amantadine hydrochloride capsules are indicated in the treatment of idiopathic Parkinson’s disease (Paralysis Agitans), postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis." ;
    rdf:object <https://identifiers.org/MONDO:0001945> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:2619> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#cohort> ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=491aea85-5a55-4a7c-b1cf-a123fea4377d> ;
    ns1:relation ns3:TreatmentIndication .

<http://purl.org/np/RAKjCVeq8YjwNP6XXn-taWvC00GILV82tCJ_FWy8T0vuE#association> a rdf:Statement ;
    rdfs:label "Temazepam is indicated for the short-term treatment of insomnia (generally 7 to 10 days)." ;
    rdf:object <https://identifiers.org/MONDO:0013600> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:9435> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4370eb4-b00d-4247-af8d-980e59fbbec6> ;
    ns1:relation ns3:TreatmentIndication .

<http://purl.org/np/RALtE7Hnj6rkqaoYCr3Pf611dZcjE7GYLMPhg4Tlzi8cQ#association> a rdf:Statement ;
    rdfs:label "Clozapine is indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state" ;
    rdf:object <https://identifiers.org/MONDO:0005090> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:3766> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RALtE7Hnj6rkqaoYCr3Pf611dZcjE7GYLMPhg4Tlzi8cQ#cohort> ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25c0c6d5-f7b0-48e4-e054-00144ff8d46c> ;
    ns1:relation <https://w3id.org/um/neurodkg/SymptomaticReliefIndication> .

<http://purl.org/np/RAMsEtsE0LCGhGrO6ArjE6vA-goNUbgvU74ukuTE8jfQA#association> a rdf:Statement ;
    rdfs:label "EMGALITY is indicated for the treatment of episodic cluster headache in adults." ;
    rdf:object <https://identifiers.org/MONDO:0043537> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/UNII:55KHL3P693> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RAMsEtsE0LCGhGrO6ArjE6vA-goNUbgvU74ukuTE8jfQA#cohort> ;
    ns1:provided_by <https://w3id.org/um/NeuroDKG> ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33a147be-233a-40e8-a55e-e40936e28db0> ;
    ns1:relation ns3:TreatmentIndication .

<http://purl.org/np/RAQDNFfhHGiatY6Vqfh-YoX1uCNsQNqLizUeHoUygRttQ#association> a rdf:Statement ;
    rdfs:label "AIMOVIG is indicated for the preventive treatment of migraine in adults." ;
    rdf:object <https://identifiers.org/MONDO:0005277> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/UNII:I5I8VB78VT> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RAQDNFfhHGiatY6Vqfh-YoX1uCNsQNqLizUeHoUygRttQ#cohort> ;
    ns1:provided_by <https://w3id.org/um/NeuroDKG> ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b998ed05-94b0-47fd-b28f-cddd1e128fd8> ;
    ns1:relation ns3:PreventionIndication .

<http://purl.org/np/RAStRuG2TC8tk3ff6If3504yWIwUTwvH8qZO-O7V18A7A#association> a rdf:Statement ;
    rdfs:label "ABSTRAL® is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving, and who are tolerant to, around-the-clock opioid therapy for their underlying persistent cancer pain." ;
    rdf:object <http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C9203> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:119915> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RAStRuG2TC8tk3ff6If3504yWIwUTwvH8qZO-O7V18A7A#cohort> ;
    ns1:provided_by <https://w3id.org/um/NeuroDKG> ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e60f00e9-2cf4-4c20-b570-1c2ea426c8c7> ;
    ns1:relation ns3:TreatmentIndication .

<http://purl.org/np/RATTKYuXt9v3tJu08ObBIT6x6-QSsIM6LQmBG4n0QkbW4#association> a rdf:Statement ;
    rdfs:label "Tolcapone tablets, USP is indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease" ;
    rdf:object <https://identifiers.org/MONDO:0005180> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:63630> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d94891be-2fef-4e39-8e35-ab7afe93e78e> ;
    ns1:relation <https://w3id.org/um/neurodkg/SymptomaticReliefIndication> .

<http://purl.org/np/RAYbeVW339VIwq71uU9xabJxqiH_KMMqhjaZWWN2cn0dA#association> a rdf:Statement ;
    rdfs:label "Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy." ;
    rdf:object <https://identifiers.org/MONDO:0016158> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:30830> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RAYbeVW339VIwq71uU9xabJxqiH_KMMqhjaZWWN2cn0dA#cohort> ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca> ;
    ns1:relation <https://w3id.org/um/neurodkg/SymptomaticReliefIndication> .

<http://purl.org/np/RA_MJldfjvpLFE5RF0tMG5eHg4tYnbjd3JOCMsQxqTNzk#association> a rdf:Statement ;
    rdfs:label "Gabapentin capsules, USP are indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. Gabapentin capsules, USP are also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 to 12 years." ;
    rdf:object <https://identifiers.org/MONDO:0005384> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:42797> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RA_MJldfjvpLFE5RF0tMG5eHg4tYnbjd3JOCMsQxqTNzk#cohort> ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0936a88f-b569-49c4-951b-14e8f6273b53> ;
    ns1:relation ns3:TreatmentIndication .

<http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#association> a rdf:Statement ;
    rdfs:label "Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing \"end of dose failure\" on levodopa therapy." ;
    rdf:object <https://identifiers.org/MONDO:0001945> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:3182> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93a0696b-b261-4262-9e06-f3180b419f8f> ;
    ns1:relation <https://w3id.org/um/neurodkg/SymptomaticReliefIndication> .

<http://purl.org/np/RAeMUX2d_wfvZinhs9mygYktXJofHWbGeuYQXvWA029oI#association> a rdf:Statement ;
    rdfs:label "OXYCODONE HCl EXTENDED-RELEASE TABLETS are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in: adults and Opioid-tolerant pediatric patients 11 years of age and older who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent" ;
    rdf:object <https://identifiers.org/MONDO:0021668> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:7859> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RAeMUX2d_wfvZinhs9mygYktXJofHWbGeuYQXvWA029oI#cohort> ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5b52ff1-21a6-4d28-9982-55b4ac195fac> ;
    ns1:relation ns3:TreatmentIndication .

<http://purl.org/np/RAnydtC12LhXGF-hxd0dL99vKOdobRbTgdtDNnbjoIytw#association> a rdf:Statement ;
    rdfs:label "Clozapine is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment" ;
    rdf:object <https://identifiers.org/MONDO:0005090> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:3766> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25c0c6d5-f7b0-48e4-e054-00144ff8d46c> ;
    ns1:relation ns3:TreatmentIndication .

<http://purl.org/np/RAoZURvqojuDxHzi2pYj0xmhs2oTGERwhNVcU12hxW49c#association> a rdf:Statement ;
    rdfs:label "ABSTRAL® is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving, and who are tolerant to, around-the-clock opioid therapy for their underlying persistent cancer pain." ;
    rdf:object <https://identifiers.org/MONDO:0021668> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:119915> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RAoZURvqojuDxHzi2pYj0xmhs2oTGERwhNVcU12hxW49c#cohort> ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e60f00e9-2cf4-4c20-b570-1c2ea426c8c7> ;
    ns1:relation ns3:TreatmentIndication .

<http://purl.org/np/RAuopBixassaSOLR7lE9c-s_3UNX7dL69EVOeY4tgp8OE#association> a rdf:Statement ;
    rdfs:label "Amantadine hydrochloride capsules are indicated in the treatment of idiopathic Parkinson’s disease (Paralysis Agitans), postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis." ;
    rdf:object <https://identifiers.org/MONDO:0005180> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:2619> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:has_population_context <http://purl.org/np/RAuopBixassaSOLR7lE9c-s_3UNX7dL69EVOeY4tgp8OE#cohort> ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=491aea85-5a55-4a7c-b1cf-a123fea4377d> ;
    ns1:relation ns3:TreatmentIndication .

<http://purl.org/np/RAxfNMrBvfY_RQfP2jDUuVScoj6WeYT3Z4QPd7hNJHelM#association> a rdf:Statement ;
    rdfs:label "Clonidine hydrochloride injection is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone" ;
    rdf:object <https://identifiers.org/MONDO:0021668> ;
    rdf:predicate ns1:treats ;
    rdf:subject <https://identifiers.org/CHEBI:3758> ;
    ns1:association_type ns1:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    ns1:provided_by "NeuroDKG" ;
    ns1:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2b11e61-b2ef-4d20-8973-a4afc6b951ae> ;
    ns1:relation ns3:TreatmentIndication .

<http://purl.org/np/RAxfNMrBvfY_RQfP2jDUuVScoj6WeYT3Z4QPd7hNJHelM#cohort> ns1:has_phenotype <https://identifiers.org/MONDO:0005070> .

<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C9203> ns1:category ns1:Disease .

<http://purl.org/np/RA2zKLyAuyeo6cHTfOknawUYaRg4M4pUeliAern9R_sJ8#medtherapy> ns4:wasDerivedFrom <http://purl.org/np/RA2zKLyAuyeo6cHTfOknawUYaRg4M4pUeliAern9R_sJ8#quote> ;
    ns3:drug <http://identifiers.org/drugbank/DB00363> ;
    ns3:targetPopulation <http://purl.org/np/RA2zKLyAuyeo6cHTfOknawUYaRg4M4pUeliAern9R_sJ8#targetpop> ;
    ns2:indicationType ns3:TreatmentIndication .

<http://purl.org/np/RA2zKLyAuyeo6cHTfOknawUYaRg4M4pUeliAern9R_sJ8#quote> ns4:value "Clozapine is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment" ;
    ns4:wasQuotedFrom <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25c0c6d5-f7b0-48e4-e054-00144ff8d46c> .

<http://purl.org/np/RA2zKLyAuyeo6cHTfOknawUYaRg4M4pUeliAern9R_sJ8#targetpop> ns3:healthCondition <http://purl.bioontology.org/ontology/MEDDRA/10065604> .

<http://purl.org/np/RA7k_pk6RqgntjF86QAJhA1fHTohtxaP1CjCCcF74Cdr0#cohort> rdfs:label "patients with a history of migraine with or without aura" ;
    ns1:category ns1:Cohort .

<http://purl.org/np/RA7wRogkbsj2tbG4zG0Mb1DiD0xuzAo0MWsw8wFwkQ45Q#cohort> rdfs:label "adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine" ;
    ns3:requiredMinAge "18" ;
    ns1:category ns1:Cohort .

<http://purl.org/np/RA8nK1kh1RiuFaqP-RHp2tpAeYCfxufGdy9GZpk3-8LLk#cohort> rdfs:label "elderly patients" ;
    ns1:category ns1:Cohort ;
    ns1:has_phenotype <https://identifiers.org/MONDO:0006694> .

<http://purl.org/np/RAG6t1GxGSN6RH1EqWONkBadVZPC5SOawHe6FAYjKujkc#cohort> rdfs:label "adults" ;
    ns3:requiredMinAge "18" ;
    ns1:category ns1:Cohort .

<http://purl.org/np/RAKNfDIO1Xe01m9uv4yFXrYrKsbwQiSdPvpK24iqCH4es#cohort> rdfs:label "elderly patients" ;
    ns1:category ns1:Cohort ;
    ns1:has_phenotype <https://identifiers.org/MONDO:0006694> .

<http://purl.org/np/RALtE7Hnj6rkqaoYCr3Pf611dZcjE7GYLMPhg4Tlzi8cQ#cohort> rdfs:label "patients (...) who are judged to be at chronic risk for re-experiencing suicidal behavior" ;
    ns1:category ns1:Cohort .

<http://purl.org/np/RAMsEtsE0LCGhGrO6ArjE6vA-goNUbgvU74ukuTE8jfQA#cohort> rdfs:label "adults" ;
    ns3:requiredMinAge "18" ;
    ns1:category ns1:Cohort .

<http://purl.org/np/RAQDNFfhHGiatY6Vqfh-YoX1uCNsQNqLizUeHoUygRttQ#cohort> rdfs:label "adults" ;
    ns3:requiredMinAge "18" ;
    ns1:category ns1:Cohort .

<http://purl.org/np/RAStRuG2TC8tk3ff6If3504yWIwUTwvH8qZO-O7V18A7A#cohort> rdfs:label "in cancer patients 18 years of age and older" ;
    ns3:requiredMinAge "18" ;
    ns1:category ns1:Cohort ;
    ns1:has_phenotype <https://identifiers.org/MONDO:0005070> .

<http://purl.org/np/RAYbeVW339VIwq71uU9xabJxqiH_KMMqhjaZWWN2cn0dA#cohort> rdfs:label "patients 7 years of age and older" ;
    ns3:requiredMinAge "7" ;
    ns1:category ns1:Cohort .

<http://purl.org/np/RA_MJldfjvpLFE5RF0tMG5eHg4tYnbjd3JOCMsQxqTNzk#cohort> rdfs:label "patients over 12 years of age with epilepsy; pediatric patients age 3 to 12 years" ;
    ns3:requiredMinAge "3" ;
    ns1:category ns1:Cohort ;
    ns1:has_phenotype <https://identifiers.org/MONDO:0005027> .

<http://purl.org/np/RAeMUX2d_wfvZinhs9mygYktXJofHWbGeuYQXvWA029oI#cohort> rdfs:label "adults and Opioid-tolerant pediatric patients 11 years of age and older" ;
    ns3:requiredMinAge "11" ;
    ns1:category ns1:Cohort .

<http://purl.org/np/RAoZURvqojuDxHzi2pYj0xmhs2oTGERwhNVcU12hxW49c#cohort> rdfs:label "cancer patients 18 years of age and older who are already receiving, and who are tolerant to, around-the-clock opioid therapy for their underlying persistent cancer pain" ;
    ns3:requiredMinAge "18" ;
    ns1:category ns1:Cohort ;
    ns1:has_phenotype <https://identifiers.org/MONDO:0005070> .

<http://purl.org/np/RAuopBixassaSOLR7lE9c-s_3UNX7dL69EVOeY4tgp8OE#cohort> rdfs:label "elderly patients" ;
    ns1:category ns1:Cohort ;
    ns1:has_phenotype <https://identifiers.org/MONDO:0006694> .

<https://identifiers.org/CHEBI:142406> ns1:category ns1:Drug .

<https://identifiers.org/CHEBI:30830> ns1:category ns1:Drug .

<https://identifiers.org/CHEBI:3182> ns1:category ns1:Drug .

<https://identifiers.org/CHEBI:3758> ns1:category ns1:Drug .

<https://identifiers.org/CHEBI:42797> ns1:category ns1:Drug .

<https://identifiers.org/CHEBI:520985> ns1:category ns1:Drug .

<https://identifiers.org/CHEBI:63630> ns1:category ns1:Drug .

<https://identifiers.org/CHEBI:7859> ns1:category ns1:Drug .

<https://identifiers.org/CHEBI:9435> ns1:category ns1:Drug .

<https://identifiers.org/HP:0032659> ns1:category ns1:Disease .

<https://identifiers.org/MONDO:0005384> ns1:category ns1:Disease .

<https://identifiers.org/MONDO:0005618> ns1:category ns1:Disease .

<https://identifiers.org/MONDO:0006966> ns1:category ns1:Disease .

<https://identifiers.org/MONDO:0013600> ns1:category ns1:Disease .

<https://identifiers.org/MONDO:0016158> ns1:category ns1:Disease .

<https://identifiers.org/UNII:I5I8VB78VT> ns1:category ns1:Drug .

<https://identifiers.org/CHEBI:119915> ns1:category ns1:Drug .

<https://identifiers.org/CHEBI:3766> ns1:category ns1:Drug .

<https://identifiers.org/CHEBI:52993> ns1:category ns1:Drug .

<https://identifiers.org/MONDO:0001945> ns1:category ns1:Disease .

<https://identifiers.org/MONDO:0005090> ns1:category ns1:Disease .

<https://identifiers.org/MONDO:0005180> ns1:category ns1:Disease .

<https://identifiers.org/MONDO:0005277> ns1:category ns1:Disease .

<https://identifiers.org/MONDO:0043537> ns1:category ns1:Disease .

<https://identifiers.org/UNII:55KHL3P693> ns1:category ns1:Drug .

<https://identifiers.org/CHEBI:2619> ns1:category ns1:Drug .

<https://identifiers.org/MONDO:0021668> ns1:category ns1:Disease .

